PMID- 33768003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian 
      Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia.
PG  - 643986
LID - 10.3389/fonc.2021.643986 [doi]
LID - 643986
AB  - BACKGROUND: Epithelial ovarian cancer (EOC) is the main subtype of ovarian cancer 
      and shows an aggressive phenotype and poor prognosis. Neuronal pentraxin II 
      (NPTX2) is a member of the neuronal pentraxin family and plays a contradictory 
      role in different tumors. However, there has been no report about the possible 
      role and effect of NPTX2 in EOC. METHODS: Bioinformatics analysis, qPCR, western 
      blotting and immunohistochemistry were used to detect the expression of NPTX2 in 
      EOC. Lentivirus-based transfection for NPTX2 overexpression or knockdown was 
      performed on the EOC cell lines A2780, HEY, SKOV3 and OVCAR-3. The effect of 
      NPTX2 on the malignant phenotype of EOC was examined through methods of MTS 
      assay, Edu assay, transwell assay, western blotting analysis, qPCR analysis, 
      luciferase reporter assay and xenograft experiment. RESULTS: EOC tissues showed 
      higher NPTX2 expression than the normal tissues with poor prognosis. NPTX2 
      overexpression can promote the proliferation, invasion, migration and 
      tumorigenesis of EOC via IL6-JAK2/STAT3 signaling pathway. Moreover, 
      hypoxia-inducible factor-1(HIF-1) can promote the transcription and expression of 
      NPTX2 under the hypoxic environment. NPTX2 knockdown abolished the 
      hypoxia-induced malignant phenotypes in ECO. CONCLUSIONS: The above results 
      suggest that NPTX2 may play a novel role in ovarian cancer's malignant phenotype 
      and act as a promising treatment target for EOC molecular therapy.
CI  - Copyright (c) 2021 Han, Lu, Li, Xia, Wen, Feng, Ju, Chen and Wu.
FAU - Han, Xiaotian
AU  - Han X
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Lu, Yechen
AU  - Lu Y
AD  - Wound Repair Center, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, 
      China.
FAU - Li, Xiaoqi
AU  - Li X
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Xia, Lingfang
AU  - Xia L
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wen, Hao
AU  - Wen H
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Feng, Zheng
AU  - Feng Z
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Ju, Xingzhu
AU  - Ju X
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Chen, Xiaojun
AU  - Chen X
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wu, Xiaohua
AU  - Wu X
AD  - Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210309
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7985451
OTO - NOTNLM
OT  - IL6-JAK2/STAT3 signaling pathway
OT  - NPTX2
OT  - epithelial ovarian carcinoma (EOC)
OT  - hypoxia
OT  - malignant phenotype
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/27 06:00
MHDA- 2021/03/27 06:01
PMCR- 2021/01/01
CRDT- 2021/03/26 07:00
PHST- 2020/12/19 00:00 [received]
PHST- 2021/01/25 00:00 [accepted]
PHST- 2021/03/26 07:00 [entrez]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2021/03/27 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.643986 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 9;11:643986. doi: 10.3389/fonc.2021.643986. eCollection 
      2021.